Last edited by Shakazahn
Saturday, August 8, 2020 | History

4 edition of Regulation of pharmaceuticals in developing countries found in the catalog.

Regulation of pharmaceuticals in developing countries

legal issues and approaches

by D. C. Jayasuriya

  • 133 Want to read
  • 27 Currently reading

Published by World Health Organization, WHO Publications Center USA [distributor] in Geneva, Albany, NY .
Written in English

    Places:
  • Developing countries.
    • Subjects:
    • Drugs -- Law and legislation -- Developing countries.,
    • Pharmacy -- Law and legislation -- Developing countries.

    • Edition Notes

      Includes bibliographical references.

      Statementby D.C. Jayasuriya.
      Classifications
      LC ClassificationsK3636 .J39 1985
      The Physical Object
      Pagination118 p. ;
      Number of Pages118
      ID Numbers
      Open LibraryOL2284278M
      ISBN 109241560894
      LC Control Number86150283

      This book applies an established analytical framework for health sector reform (Getting Health Reform Right, Oxford, ) to the performance problems of the pharmaceutical sector. The book is divided into three sections. The first section presents the basic ideas for analysis. In representatives of nearly countries at the International Conference on Population and Development (ICPD) adopted a Programme of Action, a crucial section of which included a definition of reproductive health (United Nations, ): Reproductive health is a state of complete physical.

      market has been developing, and there have been moves toward direct-to-consumer (DTC) advertising. Both influence patients’ behavior and require regulation. User charges and copayments. Practically all countries in the European Union (EU) have user charges for pharmaceuticals, and these can be an important source of revenue. kind book, Chemical Regulation in the Middle East, is an invaluable resource to help navigate the complexities of chemical compliance across a myriad of countries. Organized by country, and as outlined below, Chemical Regulation in the Middle East guides the .

        A life expectancy of 77 years ranks higher than most developing countries, but it still falls below the U.S. (79 years) and Canada (81 years). The story is the same for the infant mortality rate. Most developing countries also attempt to undercut the market power of a foreign national by allowing parallel imports -- that is, by allowing competitors, who have acquired the right to use a patent abroad, to sell a copy of the patented product locally in direct competition with the original owner of a patent.


Share this book
You might also like
French acoustical comfort standards

French acoustical comfort standards

The U.B.D. map of Gladstone (Explorer series map)

The U.B.D. map of Gladstone (Explorer series map)

Optimizing a lexical approach to instructed second language acquisition

Optimizing a lexical approach to instructed second language acquisition

Geology of the Country Around Cockermouth and Caldbeck.

Geology of the Country Around Cockermouth and Caldbeck.

Winter

Winter

Paradise lost, a poem in twelve books

Paradise lost, a poem in twelve books

Battle of the Falaise gap.

Battle of the Falaise gap.

United States government master specification for bleached cotton pillowcases.

United States government master specification for bleached cotton pillowcases.

foreign experience with income maintenance for the elderly

foreign experience with income maintenance for the elderly

Go Away, Dog

Go Away, Dog

Poet at the breakfast-table.

Poet at the breakfast-table.

Culture-centered Counseling and Interviewing Skills

Culture-centered Counseling and Interviewing Skills

Radiation of nonsinusoidal electromagnetic waves.

Radiation of nonsinusoidal electromagnetic waves.

The gold of noon

The gold of noon

Regulation of pharmaceuticals in developing countries by D. C. Jayasuriya Download PDF EPUB FB2

This book provides an introduction to some of the legal issues rel- evant to the regulation of pharmaceuticals in developing countries and describes some of the possible approaches to the establishment of a reg- ulatory framework. The book does not seek to be comprehensive in its treatment of the issues or in describing the various approaches.

Regulation of pharmaceuticals in developing countries: legal issues and approaches / D. Jayasuriya the book provides the basis for a sound understanding of each step involved in the formulation and implementation of an effective national drug policy.

The 14 chapters range in focus from procedural steps in the formulation and. Get this from a library. Regulation of pharmaceuticals in developing countries: legal issues and approaches.

[D C Jayasuriya]. Global pharmaceutical regulation: The challenge of integration for developing states Article (PDF Available) in Globalization and Health 12(1) December with 1, Reads How we measure 'reads'. The term “regulation” includes a variety of texts (e.g. guidelines, recommendations, procedures, policies, etc.) that have different legal bases and authority.

It is important to note that most countries differentiate between pharmaceutical legislation and pharmaceutical regulations [14,15] [14] [15] as follows. This article reviews, first, the rationale for price regulation of on-patent pharmaceuticals and then models of optimal regulatory structure.

It then describes the main regulatory prototypes for on-patent drugs and the empirical evidence on their effects. This is followed by a review of regulatory and reimbursement regimes for generics and evidence of their by: 2.

6 / Pharmaceutical legislation and regulation controlling deceitful drug promotion. Counterfeiting, also, has been on the rise in developed and developing countries. U.S. customs officials, for example, report that pharmaceu-ticals are one of the fastest-growing categories of.

A practical approach to pharmaceutical policy (English) Abstract. This book discusses the wide range of challenges faced by policy makers in the pharmaceutical sector, presents the current know-how in terms of policy measures, and provides specific examples of Cited by: International Cooperation, Convergence and Harmonization of Pharmaceutical Regulations: A Global Perspective provides the current status of the complex and broad phenomenon of cooperation, convergence and harmonization in the pharmaceutical sector (Part I), thoroughly evaluates its added value and its critical parameters and influencing factors (Part II) in order to recommend actions and.

Veterinary pharmaceuticals include a wide range of anti-infectives and additives in the use for animal health, nutrition, reproduction, and productivity.

Antimicrobials are among the most extensively used drugs in developing countries largely due to large population of livestock and the burden of infectious diseases. The introduction of penicillin in and other antibiotics thereafter Cited by: 1.

Unfortunately, this book can't be printed from the OpenBook. If you need to print pages from this book, we recommend downloading it as a PDF.

Visit to get more information about this book, to buy it in print, or to download it as a free PDF. INFORMATION NOTE. JULY International Regulation of Pharmaceuticals: Codification by Means of Legal Transplantation Introduction International Regulation of Pharmaceuticals draws on the introductory chapter of the book Intellectual Property, Competition and Regulatory Aspects of Medicines, jointly published inin Spanish, by Universidad Javeriana and.

The WTO and India’s Pharmaceuticals Industry: Patent Protection TRIPS and Developing Countries Book January with Reads How we measure 'reads'Author: Sudip Chaudhuri.

For patented drugs, middle-income countries pay on average 52 percent of what industrialized countries pay, while developing countries pay 27 percent of the prices charged in industrialized by: DESCRIPTION: Book annotation not available for this title.

Title: Regulatory Governance in Developing Countries Author: Minogue, Martin (EDT)/ Carino, Ledivina V. (EDT)/ Minoque, Martin Publisher: Edward Elgar Pub Publication Date: /01/07 Number of Pages: Binding Type: HARDCOVER Library of Congress: PRICE: $free shipping for all books.

Written by highly regarded academics, the book includes countries in Africa, Asia, Europe, the Middle East and South America. Keywords Access to Medicines Medicines Regulation Medicines Use Pharmaceutical Health Services Pharmacoeconomics Pharmacovigilance Pharmacy Practice Low income countries Middle income countries.

Drug Regulation: History, Present and Future 67 take informed decisions about all aspects of medi-cines without special training and access to nec-essary information.

The production of medicines, their distribution and dispensing also requires spe-cial knowledge and expertise. Among medical disci-plines clinical pharmacology could be considered as.

In general, few resources are devoted to the regulation of the promotion of pharmaceuticals in either low- or higher-income countries (Buckley ; Lexchin ), despite the evidence that promotion strongly affects prescribing and medicine use, and the public health implications and costs to society of these effects (Spurling et al.

).Cited by: 5. Dilemmas In Regulation Of The Market For Pharmaceuticals. Alan Maynard; all EU countries have a form of price regulation. In setting prices, Cited by:   I am pleased to announce a new online symposium, featuring comments about the issues that Professor Sam Halabi raises in his new book, Intellectual Property and the New International Economic Order: Oligopoly, Regulation, and Wealth Redistribution in the Global Knowledge Economy (Cambridge University Press ).

This week’s symposium, along with Halabi’s book, strikes at the [ ]. developing countries are discussed, including case studies of norplant, interferon and anti-fertility vaccines.

The book combines original historical and philosophical analysis of pharmaceutical regulation with some of the latest empirical social scientific research in the field.

It reveals both the scope and.In contrast with most other countries, the United States does not employ a form of drug price regulation to control spending on pharmaceuticals, 1 mainly because of concern that regulatory controls drive down profits and discourage the flow of capital to support the development of new molecular entities (NMEs).

2 Industry and government officials in the United States have targeted other Cited by: One possible instrument vis-a-vis the regulation of pharmaceuticals in LDC's (and in developed countries as well) is the decision by public health officials to make a particular drug available over the counter (OTC) to consumers or to require a prescription from a licensed professional.

The choice is one of balancing two competing risks.